Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: Recommendations from an international working group

Journal of Chemotherapy

Volumn 25, Issue 3, 2013, Pages 129-140

  Hara, Gabriel Levy ^a   Gould, Ian ^b   Endimiani, Andrea ^c   Pardo, Pilar Ramón ^d   Daikos, George ^e   Hsueh, Po Ren ^f   Mehtar, Shaheen ^g   Petrikkos, George ^h   Casellas, José María ⁱ   Daciuk, Lucía ^j   Paciel, Daniela ^k   Novelli, Andrea ^l   Saginur, Raphael ^m   Pryluka, Daniel ⁿ   Medina, Julio ^k   Savio, Eduardo ^k  

^a HOSPITAL DURAND   (Argentina)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF BERN   (Switzerland)

^d PAN AMERICAN HEALTH ORGANIZATION   (United States)

^e UNIVERSITY OF ATHENS   (Greece)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g STELLENBOSCH UNIVERSITY   (South Africa)

^h NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

ⁱ Sanatorio Parque   (Argentina)

^j HOSPITAL NACIONAL PROFESOR ALEJANDRO POSADAS   (Argentina)

^k DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^l UNIVERSITY OF FLORENCE   (Italy)

^m OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

ⁿ Infectious Diseases Unit   (Argentina)

more..

Author keywords

Carbapenemase producing enterobacteriaceae; Carbapenemases; Colistin; Detection; Infection control; Klebsiella pneumoniae; Multiple drug resistance; Treatment

Indexed keywords

AMINOGLYCOSIDE; AZTREONAM; BETA LACTAMASE AMPC; CARBAPENEM; CARBAPENEMASE; CEFEPIME; CEPHALOSPORIN; CHLORHEXIDINE; COLISTIMETHATE; COLISTIN; DIPICOLINIC ACID; DORIPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; POLYMYXIN B; QUINOLONE DERIVATIVE; RIFAMPICIN; SULFAMETHOXAZOLE; TIGECYCLINE;

ANTIBIOTIC SENSITIVITY; BACTERIUM DETECTION; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE INFECTION; CLASSIFICATION; DISEASE SURVEILLANCE; DRUG DOSE TITRATION; DRUG TREATMENT FAILURE; ENTEROBACTERIACEAE INFECTION; KLEBSIELLA PNEUMONIAE; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; PHARMACODYNAMICS; PREVALENCE; REVIEW;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FOSFOMYCIN; HUMANS; INFECTION CONTROL; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MOLECULAR TYPING; POLYMYXINS; PRACTICE GUIDELINES AS TOPIC;

EID: 84878266569     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000062     Document Type: Review

References (95)

1. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55:4943-60.
2. Pitout JD, Laupland KB. Extended-spectrum beta-lactamaseproducing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159-66.
3. Perez F, Endimiani A, Hujer KM, Bonomo RA. The continuing challenge of ESBLs. Curr Opin Pharmacol. 2007;7:459-69.
4. Nordmann P, Naas T, Poirel L. Global spread of carbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis. 2011;17:1791-8.
5. Cantón R, Akóva M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect. 2012;18:413-31.
6. Casellas JM. Antibacterial drug resistance in Latin America: consequences for infectious disease control. Rev Panam Salud Pública. 2011;30:519-28.
7. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012;18:263-72.
8. Orsi G, Falcone M; Venditti M. Surveillance and management of multidrug-resistant microorganisms. Expert Rev Anti Infect Ther. 2011;9:653-79.
9. Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol. 2010;300:371-9.
10. Maltezou HC. Metallo-b-lactamases in Gram-negative bacteria: introducing the era of pan-resistance? Int J Antimicrob Agents. 2009;33:405.
11. Queenan AM, Bush K. Carbapenemases: the versatile b-lactamases. Clin Microbiol Rev. 2007;20:440-58.
12. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010;65:1119-25.
13. Endimiani A, Perez F, Bajaksouzian S, Windau AR, Good CE, Choudhary Y, et al. Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility. J Clin Microbiol. 2010;48:4417-25.
14. Vading M, Samuelsen Ø, Haldorsen B, Sundsfjord AS, Giske CG. Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemase-producing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems. Clin Microbiol Infect. 2011;17:668-74.
15. Kitchel B, Rasheed JK, Endimiani A, Hujer AM, Anderson KF, Bonomo RA, et al. Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2010;54:4201-7.
16. Endimiani A, Hujer AM, Perez F, Bethel CR, Hujer KM, Kroeger J, et al. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother. 2009;63:427- 37.
17. Endimiani A, Depasquale JM, Forero S, Hujer AM, Roberts-Pollack D, Fiorella PD, et al. Emergence of bla KPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J Antimicrob Chemother. 2009;64:1102-10.
18. Overturf, G. Carbapenemases: a brief review for pediatric infectious disease specialists. Pediatr Infect Dis J. 2010;29:68- 70.
19. Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE, et al. Early dissemination of NDM-1- and OXA--181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006- 2007. Antimicrob Agents Chemother. 2011;55:1274-8.
20. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a new metallo-b-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009;53:504-54.
21. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10:597-602.
22. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. Trends Microbiol. 2011;19:588-95.
23. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis. 2011;11:355-62.
24. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother. 2012;67:1597-606.
25. Giani T, Conte V, Di Pilato V, Aschbacher R, Weber C, Larcher C, et al. Escherichia coli from Italy producing OXA-48 carbapenemase encoded by a novel Tn1999 transposon derivative. Antimicrob Agents Chemother. 2012;56:2211-3.
26. Lartigue MF, Poirel L, Poyart C, Réglier-Poupet H, Nordmann P. Ertapenem resistance of Escherichia coli. Emerg Infect Dis. 2007;13:315-7.
27. Doumith M, Ellington MJ, Livermore DM, Woodford N. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother. 2009;63:659-67.
28. Centers for Disease Control and Prevention (CDC). Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep. 2009;58:256-60.
29. Centers for Disease Control and Prevention (CDC). Guidance for control of carbapenem-resistant Enterobacteriaceae 2012 CRE Toolkit [document on the Internet]. Atlanta (GA): CDC [cited 2012 Sep 17]. Available from:http://www.cdc.gov/hai/ pdfs/cre/CRE-guidance-508.pdf
30. Galani I, Rekatsina PD, Hatzaki D, Plachouras D, Souli M, Giamarellou H. Evaluation of different laboratory tests for the detection of metallo-b-lactamase production in Enterobacteriaceae. J Antimicrob Chemother. 2008;61:548-53.
31. Tsakris A, Kristo I, Poulou A, Themeli-Digalaki K, Ikonomidis A, Petropoulou D, et al. Evaluation of boronic acid disk tests for differentiating KPC-possessing Klebsiella pneumoniae isolates in the clinical laboratory. J Clin Microbiol. 2009;47:362-7.
32. Pasteran F, Mendez T, Guerriero L, Rapoport M, Corso A. Sensitive screening tests for suspected class A carbapenemase production in species of Enterobacteriaceae. J Clin Microbiol. 2009;47:1631-9.
33. Miriagou V, Pappagianistis CC, Tzelepi E, Bou Casals J, Legakis NJ, Tzouvelekis LS. Detection of VIM-1 production in Proteus mirabilis by an imipenem dipicolinic acid double disk synergy test. J Clin Microbiol. 2010;4:667-8.
34. Seah C, Low DE, Patel SM, Melano RG. Comparative evaluation of a chromogenic agar medium, the modified Hodge test, and a battery of meropenem-inhibitor discs for detection of carbapenemase activity in Enterobacteriacae. J Clin Microbiol. 2011;49:1965-9.
35. Samra Z, Bahar J, Madar-Shapiro L, Aziz N, Israel S, Bishara J. Evaluation of CHROMagar KPC for rapid detection of carbapenem-resistant Enterobacteriaceae. J Clin Microbiol. 2008;46:3110-11.
36. Nordmann P, Girlich D, Poirel L. Detection of carbapenemase producers in Enterobacteriaceae using a novel screening medium. J Clin Microbiol. 2012;50:2761-6.
37. Spanu T, Fiori B, D'Inzeo T, Canu G, Campoli S, Giani T, et al. Evaluation of the new NucliSENS EasyQ KPC test for rapid detection of Klebsiella pneumoniae carbapenemase genes (blaKPC). J Clin Microbiol. 2012;50:2783-5.
38. Kaase M, Szabados F, Wassill L, Gatermann SG. Detection of carbapenemases in Enterobacteriaceae by a commercial multiplex PCR. J Clin Microbiol. 2012;50:3115-8.
39. Endimiani A, Hujer AM, Hujer KM, Gatta JA, Schriver AC, Jacobs MR, et al. Evaluation of a commercial microarray system for detection of SHV-, TEM-, CTX-M-, and KPC-type beta-lactamase genes in Gram-negative isolates. J Clin Microbiol. 2010;48:2618-22.
40. Bogaerts P, Hujer AM, Naas T, de Castro RR, Endimiani A, Nordmann P et al. Multicenter evaluation of a new DNA microarray for rapid detection of clinically relevant bla genes from beta-lactam-resistant gram-negative bacteria. Antimicrob Agents Chemother. 2011;55:4457-60.
41. Cuzon G, Naas T, Bogaerts P, Glupczynski Y, Nordmann P. Evaluation of a DNA microarray for the rapid detection of extended-spectrum b-lactamases (TEM, SHV and CTX-M), plasmid-mediated cephalosporinases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR and CMY-1-like/MOX) and carbapenemases (KPC, OXA-48, VIM, IMP and NDM). J Antimicrob Chemother. 2012;67:1865-9.
42. Arnold RS, Thom K, Sharma S, Phillips M, Kristie Johnson J, Morgan DJ. Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria. South Med J. 2011;104:40-45.
43. Nadkarni AS, Schliep T, Khan L, Zeana CB. Cluster of bloodstream infections caused by KPC-2 carbapenemaseproducing Klebsiella pneumoniae in Manhattan. Am J Infect Control. 2009;37:121-6.
44. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol. 2009;30:1180-5.
45. Maragakis LL. Recognition and prevention of multidrugresistant Gram-negative bacteria in the intensive care unit. Crit Care Med. 2010;38(Suppl 8):S345-51.
46. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099-106.
47. Zahar JR, Timsit JF, Garrouste-Orgeas M, Français A, Vesin A, Descorps-Declere A, et al. Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality. Crit Care Med. 2011;39:1886-95.
48. Bogdanovich T, Adams-Haduch JM, Tian GB, Nguyen MH, Kwak EJ, Muto CA, et al. Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258. Clin Infect Dis. 2011;53:373-6.
49. Mezzatesta ML, Gona F, Caio C, Petrolito V, Sciortino D, Sciacca A, et al. Outbreak of KPC-3-producing, and colistinresistant, Klebsiella pneumoniae infections in two Sicilian hospitals. Clin Microbiol Infect. 2011;17:1444-7.
50. Kontopoulou K, Protonotariou E, Vasilakos K, Kriti M, Koteli A, Antoniadou E, et al. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 b-lactamase resistant to colistin. J Hosp Infect. 2010;76:70-3.
51. Dudhani RV, Turnidge JD, Nation RL, Li J. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother. 2010;65:1984- 90.
52. Dudhani RV, Turnidge JD, Coulthard K, Milne RW, Rayner CR, Li J, et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother. 2010;54:1117-24.
53. Plachouras D, Karvanen M, Friberg L, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram- negative bacteria. Antimicrob Agents Chemother. 2009;53:3430-6.
54. Falagas ME, Rafailidis PI. Nephrotoxicity of colistin: new insight into an old antibiotic. Clin Infect Dis. 2009;48:1729-31.
55. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53:879-84.
56. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54:1720-6.
57. Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther. 2008;30:143-51.
58. Daikos GL, Skiada A, Pavleas J, Vafiadi C, Salatas K, Petrikkos G, et al. Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J Chemother. 2010;22:175-8.
59. Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest. 2010;138:1333-9.
60. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, et al. Colistin therapy for microbiologically documented multidrug-resistant Gramnegative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35:194-9.
61. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect. 2011;17:1135-41.
62. Bergen PJ, Li J, Nation RL. Dosing of colistin-back to basic PK/PD. Curr Opin Pharmacol. 2011;11:464-9.
63. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284-94.
64. Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaioannou V, Ntani G, et al. Risk factors associated with the isolation of colistin-resistant Gramnegative bacteria: a matched case-control study. Crit Care Med. 2008;36:807-11.
65. Samonis G, Matthaiou DK, Kofteridis D, Maraki S, Falagas ME. In vitro susceptibility to various antibiotics of colistinresistant Gram-negative bacterial isolates in a general tertiary hospital in Crete, Greece. Clin Infect Dis. 2010;50:1689-91.
66. Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2011;66:946-7.
67. Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2008;62:1311-8.
68. Mazzei T, Novelli A. Pharmacological rationale for antibiotic treatment of intra-abdominal infections. J Chemother. 2009;21(Suppl 1):S19-29.
69. Bhavnani SM, Rubino CM, Hammel JP, Forrest A, Dartois N, Cooper A, et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother. 2012;56: 1065-72.
70. Falagas ME, Karageorgopoulos DE, Nordmann P. Therapeutic options for infections with Enterobacteriaceae producing carbapenem hydrolyzing enzymes. Future Microbiol. 2011;6:653-66.
71. Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein JT, Welte T. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents. 2009;34:101-2.
72. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother. 2008;62:895-904.
73. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis. 2008;46:567-70.
74. FDA Drug Safety Communication. Increased risk of death with tygacil (tigecycline) compared to other antibiotics used to treat similar infections [Internet]. Silver Spring (MD): FDC [cited 2012 Nov 3]. Available from:http://www.fda.gov/Drugs/ DrugSafety/ucm224370.htm
75. Bodmann KF, Heizmann WR, von Eiff C, Petrik C, Löschmann PA, Eckmann C. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities. Chemotherapy. 2012;58:282-94.
76. Bratu S, Tolaney P, Karumudi U, Quale J, Mooty M, Nichani S, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother. 2005;56:128-32.
77. Popovic M, Steinort D, Pillai S, Joukhadar C. Antimicrobial susceptibility of gram negative non urinary bacteria to fosfomycin and other antimicrobials. Future Microbiol. 2010;5:961-70.
78. Endimiani A, Patel G, Hujer KM, Swaminathan M, Perez F, Rice LB, et al. In vitro activity of fosfomycin against blaKPCcontaining Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother. 2010;54:526-9.
79. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME, et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenemresistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect. 2010;16:184-6.
80. Karageorgopoulos DE, Miriagou V, Tzouvelekis L, Spyridopoulou K, Daikos GL. Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. J Antimicrob Chemother. 2012;67:2777-9.
81. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56:2108-13.
82. Daikos GL, Petrikkos P, Psichogiou M, Kosmidis C, Vryonis E, Skoutelis A, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother. 2009;53:1868-73.
83. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17:1798-803.
84. Tzouvelekis LS, Markogiannakis A., Psichogiou PT, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25:682-707.
85. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943-50.
86. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol. 2003;43:1116-23.
87. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect. 2012;18:439-48.
88. Pournaras S, Vrioni G, Neou E, Dendrinos J, Dimitroulia E, Poulou A. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by timekill assay. Int J Antimicrob Agents. 2011;37:244-7.
89. Elemam A, Rahimian J, Doymaz M. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol. 2010;48:3558-62.
90. Gijón E, Curiao T, Baquero F, Coque TM, Cantón R. Fecal carriage of carbapenemase-producing Enterobacteriaceae: a hidden reservoir on hospitalized and nonhospitalized patients. J Clin Microbiol. 2012;50:1558-63.
91. European Centre for Disease Prevention and Control. Risk assessment on the spread of carbapenemase-producing Enterobacteriaceae (CPE) through patient transfer between healthcare facilities, with special emphasis on cross-border transfer. Stockholm: ECDC; 2011.
92. Borer A, Eskira S, Nativ R, Saidel-Odes L, Riesenberg K, Livshiz-Riven I, et al. A multifaceted intervention strategy for eradication of a hospital-wide outbreak caused by carbapenemresistant Klebsiella pneumoniae in Southern Israel. Infect Control Hosp Epidemiol. 2011;32:1158-65.
93. Cohen MJ, Block C, Levin PD, Schwartz C, Gross I, Weiss Y, et al. Institutional control measures to curtail the epidemic spread of carbapenem-resistant Klebsiella pneumoniae: a 4-year perspective. Infect Control Hosp Epidemiol. 2011;32:673- 8.
94. Ciobotaro P, Oved M, Nadir E, Bardenstein R, Zimhony O. An effective intervention to limit the spread of an epidemic carbapenem-resistant Klebsiella pneumoniae strain in an acute care setting: from theory to practice. Am J Infect Control. 2011;39:671-7.
95. McGuinn M, Hershow RC, Janda WM. Escherichia coli and Klebsiella pneumoniae carbapenemase in long-term care facility, Illinois, USA. Emerg Infect Dis. 2009;15:988-9.